Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy
Seeking Alpha assigns Ligand Pharmaceuticals a Buy rating, citing 85% year-over-year royalty growth from Filspari and the addition of a new FSGS indication. It also points to XOMA’s $12.3 million Q3 royalty contribution and pipeline as sources of revenue diversification and potential catalysts.
Why it matters — The item highlights Filspari’s royalty growth and XOMA’s contribution as factors shaping Ligand’s revenue mix and future prospects.